#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	12656	16S	1529	1529	99.93	16S.l6.c4.ctg.1	1998	628.2	0	.	n	.	0	C1450T	SNP	1450	1450	C	1701	1701	T	740	T	651	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	531	12656	16S	1529	1529	99.93	16S.l6.c4.ctg.1	1998	628.2	1	SNP	n	C1184T	0	.	.	1184	1184	C	1435	1435	C	741	C	664	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23026	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3511	653.3	0	.	n	.	0	G1337A	SNP	1337	1337	G	1698	1698	A	788	A,G	712,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23026	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3511	653.3	0	.	n	.	0	T1971C	SNP	1971	1971	T	2332	2332	C	754	C	676	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23026	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3511	653.3	1	SNP	n	A2045G	0	.	.	2045	2045	A	2406	2406	A	700	A	641	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	531	23026	23S	2890	2890	99.93	23S.l15.c4.ctg.1	3511	653.3	1	SNP	n	C2597T	0	.	.	2597	2597	C	2958	2958	C	711	C	647	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
folP.WHO_U_01433c	folP.WHO_U_01433c	1	1	27	1664	folP	852	852	99.88	folP.l6.c4.ctg.1	1565	105.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	4298	gyrA	2751	2751	99.82	gyrA.l15.c17.ctg.1	3448	124.3	0	.	p	.	0	D515N	NONSYN	1543	1545	GAC	1868	1870	AAC	136;137;137	A;A;C	126;124;124	.	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	4298	gyrA	2751	2751	99.82	gyrA.l15.c17.ctg.1	3448	124.3	1	SNP	p	S91F	0	.	.	271	273	TCC	596	598	TCC	164;164;161	T;C;C	140;141;140	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	4298	gyrA	2751	2751	99.82	gyrA.l15.c17.ctg.1	3448	124.3	1	SNP	p	D95N	0	.	.	283	285	GAC	608	610	GAC	157;156;155	G;A;C	144;141;140	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	539	4298	gyrA	2751	2751	99.82	gyrA.l15.c17.ctg.1	3448	124.3	1	SNP	p	D95G	0	.	.	283	285	GAC	608	610	GAC	157;156;155	G;A;C	144;141;140	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1342	mtrR	633	633	99.21	mtrR.l6.c30.ctg.1	1307	102.2	0	.	p	.	0	A39T	NONSYN	115	117	GCC	507	509	ACC	166;163;165	A;C;C	147;148;150	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1342	mtrR	633	633	99.21	mtrR.l6.c30.ctg.1	1307	102.2	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	705	707	CAC	176;176;176	C,T;A;C	164,1;163;164	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1342	mtrR	633	633	99.21	mtrR.l6.c30.ctg.1	1307	102.2	0	.	p	.	0	E117K	NONSYN	349	351	GAA	741	743	AAA	166;165;165	A,G;A;A	151,1;151;151	.	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	539	1342	mtrR	633	633	99.21	mtrR.l6.c30.ctg.1	1307	102.2	1	SNP	p	G45D	0	.	.	133	135	GGC	525	527	GGC	159;158;158	G;G;C	145;143;142	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	766	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1005	76.1	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4274	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2800	152.1	0	.	p	.	0	V435A	NONSYN	1303	1305	GTG	1553	1555	GCA	160;162;165	G;C;A	142;141;143	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4274	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2800	152.1	0	.	p	.	0	V596I	NONSYN	1786	1788	GTT	2036	2038	ATT	182;185;185	A;T,C;T	157;158,1;161	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4274	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2800	152.1	1	SNP	p	D86N	0	.	.	256	258	GAC	506	508	GAC	202;202;202	G;A;C	184;176;182	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4274	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2800	152.1	1	SNP	p	S87R	0	.	.	259	261	AGT	509	511	AGT	202;201;200	A;G;T	182;181;180	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4274	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2800	152.1	1	SNP	p	S87I	0	.	.	259	261	AGT	509	511	AGT	202;201;200	A;G;T	182;181;180	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4274	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2800	152.1	1	SNP	p	S87W	0	.	.	259	261	AGT	509	511	AGT	202;201;200	A;G;T	182;181;180	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	539	4274	parC	2304	2304	99.7	parC.l15.c4.ctg.1	2800	152.1	1	SNP	p	S88P	0	.	.	262	264	TCC	512	514	TCC	202;204;202	T,C;C;C	181,1;185;184	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	3834	parE	1986	1986	99.95	parE.l15.c4.ctg.1	2587	147.5	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1500	1502	GGC	201;199;195	G;G;C	182;181;176	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.22.001	penA.22.001	1	1	27	3648	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2282	158.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1147	1149	GCA	177;179;185	G;C;A	160;160;169	penA.22.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3648	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2282	158.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1150	1152	ATC	185;184;186	A;T;C	168;166;168	penA.22.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3648	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2282	158.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1162	1164	GTG	189;191;193	G;T;G	170;170;172	penA.22.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3648	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2282	158.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1162	1164	GTG	189;191;193	G;T;G	170;170;172	penA.22.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3648	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2282	158.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1666	1668	ACC	162;163;162	A;C,A;C	144;146,1;147	penA.22.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3648	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2282	158.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1720	1722	GCG	163;160;160	G;C;G	134;123;124	penA.22.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3648	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2282	158.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1720	1722	GCG	163;160;160	G;C;G	134;123;124	penA.22.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3648	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2282	158.8	1	SNP	p	G543S	0	.	.	1627	1629	GGT	1843	1845	GGT	148;149;151	G;G;T	131;130;132	penA.22.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3648	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2282	158.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1852	1854	GGC	153;152;152	G;G;C	135;134;133	penA.22.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.22.001	penA.22.001	1	1	27	3648	penA	1752	1752	100.0	penA.l15.c4.ctg.1	2282	158.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1870	1872	CCG	148;148;147	C;C,A;G	103;115,1;104	penA.22.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	4872	ponA	2397	2397	99.96	ponA.l6.c30.ctg.1	3139	154.6	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
porA.NCCP11945	porA.NCCP11945	1	0	531	1884	porA	1146	1146	99.65	porA.l15.c4.ctg.1	1676	111.7	0	.	p	.	0	M83fs	FSHIFT	247	247	A	454	454	C	146	C,T	128,1	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	180	porB1a	984	284	90.28	porB1a.l15.c17.ctg.2	313	9.9	0	.	p	.	0	H217N	NONSYN	649	651	CAT	50	52	AAT	9;9;10	A;A;T	3;3;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	180	porB1a	984	284	90.28	porB1a.l15.c17.ctg.2	313	9.9	0	.	p	.	0	D218N	NONSYN	652	654	GAT	53	55	AAT	10;9;9	A;A;T	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	180	porB1a	984	284	90.28	porB1a.l15.c17.ctg.2	313	9.9	0	.	p	.	0	A222V	NONSYN	664	666	GCT	65	67	GTT	8;7;7	G;T;T	4;4;4	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	180	porB1a	984	284	90.28	porB1a.l15.c17.ctg.2	313	9.9	0	.	p	.	0	V226A	NONSYN	676	678	GTA	77	79	GCG	6;5;6	G;C;G	4;4;5	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	180	porB1a	984	284	90.28	porB1a.l15.c17.ctg.2	313	9.9	0	.	p	.	0	.	MULTIPLE	700	702	ACT	100	102	GTA	5;4;4	G;T;A	4;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	180	porB1a	984	284	90.28	porB1a.l15.c17.ctg.2	313	9.9	0	.	p	.	0	N237K	NONSYN	709	711	AAC	109	111	AAA	4;4;4	A;A;A	3;3;3	.	.
porB1a.WHO_N_02200c	porB1a.WHO_N_02200c	1	0	528	180	porB1a	984	284	90.28	porB1a.l15.c17.ctg.2	313	9.9	0	.	p	.	0	D238fs	FSHIFT	712	712	G	112	112	G	6	G	5	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2404	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1368	172.5	0	.	p	.	0	V135M	NONSYN	403	405	GTG	586	588	ATG	216;215;218	A;T;G	191;190;192	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2404	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1368	172.5	0	.	p	.	0	K143Q	NONSYN	427	429	AAA	610	612	CAA	200;198;199	C;A;A	177;179;179	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2404	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1368	172.5	0	.	p	.	0	E212D	NONSYN	634	636	GAA	817	819	GAT	201;199;199	G;A;T	183;182;180	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2404	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1368	172.5	0	.	p	.	0	H213D	NONSYN	637	639	CAT	820	822	GAT	197;195;195	G;A;T	180;179;178	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2404	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1368	172.5	0	.	p	.	0	I218M	NONSYN	652	654	ATC	835	837	ATG	203;203;203	A;T;G	184;184;182	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2404	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1368	172.5	0	.	p	.	0	R257K	NONSYN	769	771	AGG	952	954	AAG	186;190;189	A;A;G	171;174;174	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2404	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1368	172.5	0	.	p	.	0	S295N	NONSYN	883	885	AGT	1066	1068	AAT	185;187;187	A;A;T	164;166;168	.	.
porB1b.WHO_P_02204c	porB1b.WHO_P_02204c	1	1	539	2404	porB1b	1047	1047	99.04	porB1b.l15.c30.ctg.1	1368	172.5	1	SNP	p	G120K	0	.	.	358	360	GGC	541	543	GGC	204;206;207	G;G;C	187;188;188	porB1b.WHO_P_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	porB3.Neisseria_meningitidis_serogroup_A_Z2491_v1_00376	1	0	528	156	porB3	990	96	95.83	porB3.l6.c30.ctg.2	325	8.2	0	.	p	.	0	L253A	NONSYN	757	759	TTG	44	46	GCG	10;10;10	G;C;G	9;9;9	.	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	9008	rpoB	4179	4179	99.95	rpoB.l15.c30.ctg.1	4911	183.1	0	.	p	.	0	T6I	NONSYN	16	18	ACC	430	432	ATC	174;174;176	A;T;C	159;160;160	.	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	9008	rpoB	4179	4179	99.95	rpoB.l15.c30.ctg.1	4911	183.1	1	SNP	p	H553N	0	.	.	1657	1659	CAT	2071	2073	CAT	199;201;203	C;A;T	176;173;175	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_F_02142c	rpsJ.WHO_F_02142c	1	1	27	1008	rpsJ	312	312	100.0	rpsJ.l15.c4.ctg.1	1056	94.9	1	SNP	p	V57M	0	.	.	169	171	GTG	547	549	GTG	238;239;240	G,A;T;G	212,1;212;213	rpsJ.WHO_F_02142c:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
tetM.WHO_G_pTetM_00047	tetM.WHO_G_pTetM_00047	1	0	27	15956	tetM	1920	1920	100.0	tetM.l15.c4.ctg.1	2381	664.8	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	Tetracycline resistance
